All News
TNF Inhibition and Heart Failure
Clinicians often face the issue of using a TNF inhibitor (TNFi) in patients with heart failure or cardiac disease. Here are the facts and data necessary to make a cogent decision to use or avoid TNFi.
Read ArticleLess Treatment, Responses and Safety in Elder-Onset Rheumatoid Arthritis
A recent review compared elderly-onset rheumatoid arthritis (EORA) to those with younger-onset rheumatoid arthritis (YORA) to assess treatment responses and safety issues with biologics and DMARDS. EORA is generally defined as the onset of rheumatoid arthritis after age 60 years.
Read ArticleSubclinical Synovitis in Psoriasis Portends Future Psoriatic Arthritis
It is estimated that nearly 30% of psoriasis patients will develop psoriatic arthritis (PsA). This prevalence was studied by performing MRI scans on asymptomatic psoriasis (n=56) and 30 control patients without arthritis.
Read ArticleTools, Brains & Organizers for Your Phone
Most people can’t live without their cell phone. But does the device define the modern medicine man and woman?
Read ArticleRheumatoid Arthritis Alone is Not a Risk for Post-Op CV Events
Using hospitalization claims from 7 states, reasearchers studied the risk of cardiovascular outcomes following surgery in rheumatoid arthritis (RA) patients. (Citation source http://buff.ly/1TDsVG6)
Read ArticleOral Prednisolone and NSAIDs Equipotent in Acute Gout
An emergency department based study evaluated the efficacy and safety of oral prednisolone versus indomethacin in 416 patients with acute gout in a multicenter, double-blind, randomized trial.
Read ArticleFebuxostat Safe in Gout with Moderate-Severe Renal Impairment
Renal impairment is a risk factor for gout and a barrier to optimal gout management. Many of the drugs used to treat gout require adjustment in those with renal disease.
Read ArticlePulmonary Hypertension Earlier and More Severe in Men with Scleroderma
Pulmonary hypertension is an uncommon complication of systemic sclerosis (SSc) and historically thought to slowly evolve in those with limited scleroderma over many years.
Read ArticleLupus Flares After Renal Transplant
Whether lupus activity is ameliorated by end-stage renal disease (ESRD) or transplantation has been debated.
Read ArticleRWCS 2016 - Updates in AS, PsA and Lupus
Update on Ankylosing Spondylitis and Spondyloarthritis
Read ArticleSmoking and Age Linked to Development of Inflammatory Arthritis
A prospective cohort of RA first-degree relatives were prospectively studied for genetic and environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies that may influence future development of inflammatory joint symptoms over a 2 year 
Read ArticleWhat To Do After Teriparatide?
Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?
Read ArticleFDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).
Read ArticleRacial Disparity in Cardiovascular Risks with Connective Tissue Disorders
Cardiovascular events account for significant morbidity and mortality in patients with rheumatoid arthritis (RA) and other connnective tissue disorders (CTD). Investigators analyzed health records from a large U.S.
Read ArticleYoung Lupus Patients Have Higher Mortality Risk
A retrospective study examined mortality rates by comparing 2740 UK lupus patients who were matched 1:4 with controls from the UK Clinical Practice Research Datalink between 1999 and 2012. (Citation source http://buff.ly/1nJWKIT)
Read ArticleCochrane Review:NSAIDs Equally Effective for Axial Spondyloarthritis
Until the advent of TNF inhibitor therapy, nonsteroidal antiinflammatory drugs (NSAIDs) were the only effective treatment for ankylosing spondylitis or spondyloarthritis (SpA). More recently, several reports have suggested clinical and radiographic benefits to sustained NSAID use.
Read ArticleRheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer
Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.
Read ArticleComorbidities Start Early in Rheumatoid Arthritis
A Northern Sweden early rheumatoid arthritis (RA) cohort of 950 patients was enrolled starting in 1995. A validated questionnaire at RA onset (T0) and after 5 years (T5) after enrollment. Currently, 726 of these have had RA for ≥5 years.
Read ArticleNo Significant Increased Risk with TNF Inhibitors During Pregnancy
A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)
Read ArticleRisk of Multiple Sclerosis with TNF Inhibitor Therapy
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Read Article